3AC.F · Actinogen Medical Limited

-

Please sign in to comment on 3AC.F

1 Comment

Admin

4 years ago

Actinogen Medical Limited is currently in a long term uptrend where the price is trading 155.1% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Actinogen Medical Limited's total revenue sank by 0.0% to $370K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 108.5% to $533K since the same quarter in the previous year.

Based on the above factors, Actinogen Medical Limited gets an overall score of 3/5.

Exchange	F
CurrencyCode	EUR
ISIN	AU000000ACW3
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Market Cap	53M
Target Price	None
Beta	1.13
Dividend Yield	None

ABOUT

Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

3AC.F · Actinogen Medical Limited

-

Actinogen Medical Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Actinogen Medical Limited using a moving average strategy